Phase IIa placebo-controlled study of odanacatib in postmenopausal women with osteoporosis previously treated with alendronate

Phase 2, randomised, double-blind trial in postmenopausal osteoporosis and osteoporosis comparing Odanacatib with Placebo (2 arms). Primary endpoint: Percent change from baseline in femoral neck bone mineral density at 24 months. Started Jan 2009; status: completed.